
Leidos Hld (LDOS) Stock Forecast & Price Target
Leidos Hld (LDOS) Analyst Ratings
Bulls say
Leidos Holdings Inc has exhibited significant improvement in its Health & Civil segment, with EBIT margins rising from 14.5% in 2023 to 22.5% in 2024, and reaching an impressive 24.3% in the first half of 2025, driven by increased exam volumes and completed claims. The company's growth is supported by strategic initiatives from the Department of Veterans Affairs aimed at reducing the claims backlog to 60,000 by the end of 2025, which is expected to bolster near-term volume strength. Overall, the company's operational scale advancements and enhancing margins indicate a positive outlook for future performance.
Bears say
Leidos Holdings Inc. faces a negative outlook primarily due to projected margin declines in the second half of 2025 compared to the first half, indicating a potential contraction in profitability. Additionally, there are significant risks associated with the budget environment, which could further undermine investor sentiment if margins deteriorate markedly. A crucial factor contributing to this outlook is the anticipated decrease in medical exam volumes, which may exert additional pressure on margins within the company's health services segment.
This aggregate rating is based on analysts' research of Leidos Hld and is not a guaranteed prediction by Public.com or investment advice.
Leidos Hld (LDOS) Analyst Forecast & Price Prediction
Start investing in Leidos Hld (LDOS)
Order type
Buy in
Order amount
Est. shares
0 shares